Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), ...

There was no meaningful protection from major cardiac events after MI, reported investigators of the multinational placebo-controlled trial that is challenging common clinical practice.

Any cardiovascular protection from colchicine in heart attack survivors seemed to be debunked with a better-powered ...

Both studies were presented at the American College of Rheumatology (ACR) annual meeting.

WASHINGTON, DC—The routine use of colchicine, an anti-inflammatory agent with a challenging side-effect profile, fails to reduce the risk of major adverse cardiovascular events when used in patients ...

Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events. In this multicenter trial with a 2-by-2 ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Any cardiovascular protection from colchicine in heart attack survivors seemed to be debunked with a better-powered ...

Acetaminophen use, which was allowed as needed, was not taken less often by patients assigned to colchicine. (HealthDay News) — Colchicine fails to improve knee pain, function, or size of ...

COLCHICINE has been shown to inhibit deoxyribonuclease and de-phosphorylation and de-amination of deoxyribonucleotides 1. The beneficial effect of colchicine in gout is possibly due to the effect ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

The largest trial to examine the impact of colchicine in acute myocardial infarction (MI) found that both acute and long-term colchicine use did not reduce cardiovascular death, myocardial ...